<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049864</url>
  </required_header>
  <id_info>
    <org_study_id>BelarusianPediatric</org_study_id>
    <nct_id>NCT04049864</nct_id>
  </id_info>
  <brief_title>DNA Vaccination Against Neuroblastoma</brief_title>
  <official_title>Pilot Clinical Study of DNA Vaccination Against Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belarusian Research Center for Pediatric Oncology, Hematology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belarusian Research Center for Pediatric Oncology, Hematology and Immunology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is pilot open-label study to evaluate the safety and immunogenicity of a DNA vaccine&#xD;
      strategy in relapsed neuroblastoma patients following chemotherapy and HSC transplantation.&#xD;
      The combined form of the vaccine includes an intramuscular injection of the&#xD;
      DNA-polyethylenimine conjugate and oral administration using the attenuated Salmonella&#xD;
      enterica as DNA vaccine carriers.&#xD;
&#xD;
      Objectives of the study:&#xD;
&#xD;
        1. To assess safety and document local and systemic toxicity to combined DNA vaccine&#xD;
&#xD;
        2. To determine immunogenicity of the vaccine&#xD;
&#xD;
        3. To evaluate clinical response to vaccination. Control of minimal residual disease in&#xD;
           bone marrow and duration of remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DNA vaccine construction includes chimeric fusion of neuroblastoma-associated antigen and&#xD;
      potato virus X coat protein (PVXCP) as an immune enhancer. In each course vaccine for one&#xD;
      antigen is applies. The selection of antigens is carried out after analyzing of their&#xD;
      expression in the tumor biopsy material by PCR and IHC. The list of antigens used in the&#xD;
      study: tyrosine hydroxylase (TH), Phox2B, Survivin, MAGEA1, MAGEA3, PRAME. The antigens with&#xD;
      the highest level of expression in the tumor sample of each patient are selected for&#xD;
      vaccination.&#xD;
&#xD;
      Vaccination schedule for each patient includes three courses of vaccination. One course&#xD;
      includes three administrations of vaccines against a single antigen. Vaccination is repeated&#xD;
      at intervals of 1 week (plus minus 3 working days). Break between courses - 3-4 weeks. Each&#xD;
      vaccination includes an injection and taking a capsule with a dose of bacteria.&#xD;
&#xD;
      For intramuscular injection, we use conjugate (polyplex) DNA with linear polyethylenimine 20&#xD;
      kDa (PEI). One dose includes 400 µg of DNA and 500 µg of PEI. When administered orally, the&#xD;
      patient receives a suspension 10^10 CFU of an attenuated Salmonella enterica serovar&#xD;
      typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.&#xD;
&#xD;
      Before and during vaccination, an accompanying chemotherapy is carried out, including&#xD;
      cyclophosphamide, propranolol, celecoxib and lenalidomide. Cyclophosphamide is prescribed&#xD;
      three days before the start of each vaccination course in a single dose of 300 mg / m2.&#xD;
      Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7&#xD;
      days before the first vaccination course and ending on the day of the last vaccination course&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events experienced by subjects</measure>
    <time_frame>for 3 months from the first vaccination</time_frame>
    <description>To assess the safety of the DNA-PEI and Salmonella vaccines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response to the vaccine</measure>
    <time_frame>In check point after 2nd course (9 week after first vaccine)</time_frame>
    <description>Immunogenicity will be evaluated by assessing T-cell IFN-γ production in ELISPOT and PVXCP antibody production by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response to the vaccine</measure>
    <time_frame>In check point after 3rd course (14 week after the first vaccine)</time_frame>
    <description>Immunogenicity will be evaluated by assessing T-cell IFN-γ production in ELISPOT and PVXCP antibody production by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal residual disease - MRD</measure>
    <time_frame>up to 4 weeks after the last vaccination</time_frame>
    <description>MRD in bone marrow measured by RQ-PCR and flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - PFS</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time from treatment to date of first documented progression or date of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Relapsed Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive the vaccine and be followed per the schedule of procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA vaccine</intervention_name>
    <description>conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>DNA-PEI polyplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Salmonella oral vaccine</intervention_name>
    <description>suspension 10^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The diagnosis of neuroblastoma recurrence with morphological / cytological&#xD;
             confirmation;&#xD;
&#xD;
          2. The presence of tumor tissue for biopsy;&#xD;
&#xD;
          3. The absence of progression or a large tumor mass (bulky disease);&#xD;
&#xD;
          4. The physical status on the scale of ECOG 0 - 2.&#xD;
&#xD;
          5. Life expectancy of at least 12 months&#xD;
&#xD;
          6. Indicators of cellular immunity of the blood: lymphocytes - at least 1 * 10^9;&#xD;
&#xD;
          7. Availability of written informed consent of the patient and his parents (legal&#xD;
             representatives) to participate in this protocol.&#xD;
&#xD;
          8. Compliance of parents (legal representatives) and the patient himself with&#xD;
             participation in the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A. Based on the anamnesis:&#xD;
&#xD;
          1. The presence of any primary immunodeficiency;&#xD;
&#xD;
          2. The presence of a primary multiple malignant tumor;&#xD;
&#xD;
          3. The presence of autoimmune diseases in history (except thyroiditis);&#xD;
&#xD;
          4. Polyalgia;&#xD;
&#xD;
          5. Severe diseases, including those with severe symptoms, untreated inflammatory and&#xD;
             infectious processes, due to which the patient cannot receive treatment in accordance&#xD;
             with the study protocol.&#xD;
&#xD;
          6. Socioeconomic or geographical circumstances that cannot guarantee proper compliance&#xD;
             with the requirements of the protocol for treatment and further observation.&#xD;
&#xD;
        B. based on survey data:&#xD;
&#xD;
          1. The absence of expression in the tumor tissue of two or more antigens used in the&#xD;
             protocol;&#xD;
&#xD;
          2. The level of peripheral blood leukocytes &lt;1.5 × 10^9 /L, platelet &lt;50.0 × 10^9 /L,&#xD;
             Hemoglobin less than 80 g / L;&#xD;
&#xD;
          3. Positive tests for human immunodeficiency virus (HIV), hepatitis B or C.&#xD;
&#xD;
          4. Severe impaired liver function - the levels of AST / SGOT or ALT / SGPT exceed the&#xD;
             upper limit of normal 5 times or more.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inna V Proleskovskaya, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Belarussian Research Center for Pediatric Oncology, Hematology and Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander N Meleshko, PhD</last_name>
    <phone>+375296940023</phone>
    <email>alexander.meleshko@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Belarussian Research Center for Pediatric Oncology, Hematology and Immunology</name>
      <address>
        <city>Minsk</city>
        <state>Minsk Region</state>
        <zip>223053</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+375 17 265 42 22</phone>
      <email>mail@oncology.by</email>
    </contact>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Belarusian Research Center for Pediatric Oncology, Hematology and Immunology</investigator_affiliation>
    <investigator_full_name>Alexander Meleshko</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>neuroblastoma</keyword>
  <keyword>DNA vaccine</keyword>
  <keyword>Salmonella vaccine</keyword>
  <keyword>polyethylenimine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

